Coronary Heart Disease Detection Test Merges Epigenetic and Genetic Biomarkers with Artificial Intelligence, Offering Remote and Scalable Deployment Capabilities Across the Nation CHICAGO – Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer in AI-driven...
The study represents a significant breakthrough in understanding the potential for reversing and measuring epigenetic changes associated with coronary heart disease after therapeutic intervention CHICAGO – Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a...
CHICAGO – Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, announced the introduction of the Actionable Clinical IntelligenceTM (ACI) platform to expand the information available to...
CHICAGO – Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, announced the introduction of the Actionable Clinical IntelligenceTM (ACI) platform to expand the information available to...
CHICAGO – Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced a partnership with Connect Clinic to help MidWest/South Central self-insured employers build access to heart disease initiatives. These states...
This research-use-only offering supports the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases. CHICAGO – Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular...